In order to prevent spam,
this email address cannot be copied.
Schizophrenia Research Forum: Researcher Profile - Rajiv Tandon
Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Researcher Profile - Rajiv Tandon

First Name:Rajiv
Last Name:Tandon
Title:Chief of Psychiatry
Advanced Degrees:MD
Affiliation:State of Florida Program of Mental Health
Street Address 1:1317 Winewood Boulevard
Street Address 2:Building 6, Room 235
Zip/Postal Code:32309
Email Address:
(view policy) 
Member reports no financial or other potential conflicts of interest. [Last Modified: 20 October 2005]
View all comments by Rajiv Tandon
Clinical Interests:
Research Focus:
Chemistry/pharmacology, Clinical trials, Pharamacology, Phenomenology/diagnosis
Work Sector(s):
State Government, University
Reasearcher Bio
Rajiv Tandon is currently the Chief of Psychiatry, Florida Department of Children and Families. He was on the faculty of the Department of Psychiatry at the University of Michigan Medical Center, Ann Arbor, Michigan, from 1987-2004, where he was a tenured Professor of Psychiatry. He is a member of the Board of Directors of the National Schizophrenia Foundation and a member of the Scientific Council of the National Alliance for the Mentally Ill. He was a member of State of Michigan Mental Health Commission in 2003-2004. Dr Tandon has authored 250 scientific publications and given over 500 national and international scientific presentations. He has received several awards for research and teaching in schizophrenia, including the American Psychiatric Association Young Psychiatrist Researcher of the Year award in 1993, the inaugural NARSAD Gerald Klerman award in 1995, and the 1997 FuturPsych award for outstanding achievement in schizophrenia research. He has been included in every edition of THE BEST DOCTORS IN AMERICA since 1993.
Top Papers
1. Tandon R, Greden JF : Cholinergic hyperactivity and negative schizophrenic symptoms : A model of dopaminergic/cholinergic interactions in schizophrenia. Archives of General Psychiatry. 46: 745-753, 1989.

2. Tandon R, Mann N, Eisner B, Coppard N : Effect of anticholinergic medication on
positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Research, 31: 235-241, 1990.

3. Tandon R, Mazzara C, DeQuardo J, Craig KA, Meador-Woodruff JH, Goldman R, Greden JF : Dexamethasone suppression test in schizophrenia : Relationship to symptomatology, ventricular enlargement, and outcome. Biological Psychiatry, 29: 953-964, 1991.

4. Tandon R, Shipley J, Taylor S, Greden JF, Eiser A, DeQuardo J, Goodson J : Electroencephalographic sleep abnormalities in schizophrenia : Relationship to positive/negative symptoms and prior neuroleptic treatment, Archives of General Psychiatry, 49: 185-194, 1992.

5. Tandon R, Goldman R, DeQuardo JR, Perez M, Goodson J, Jibson M: Covariance of positive and negative symptoms during clozapine treatment in schizophrenia. Journal of Psychiatric Research 27: 341-347, 1993.

6. Tandon R, Milner K, Jibson M: Antipsychotics from theory to practice: Integrating clinical and basic data. Journal of Clinical Psychiatry, 60 [Suppl 8]: 21-28, 1999.

7. Tandon R, Taylor SF, DeQuardo JR, Shipley JE, Eiser A, Jibson MD: The cholinergic system in schizophrenia reconsidered: Anticholinergic modulation of sleep and symptom profiles. Neuropsychopharmacology, 22: S189-202, 1999.

8. Tandon R: Moving beyond findings: concepts and model-building in schizophrenia.
Journal of Psychiatric Research, 33: 467-471, 1999.

9. Tandon R, DeQuardo JR, Taylor SF, McGrath M, Jibson MD, Eiser A, Goldman M: Psychotic phasic and deficit enduring subtypes of negative symptoms: Biological markers and relationship to outcome. Schizophrenia Research, 45: 191-201, 2000. (Erratum published in 51:185)

10. Tandon R, Fleischhacker WW: Comparative efficacy of antipsychotics in the treatment of schizophrenia: A critical assessment. Schizophrenia Research, 79: 145-155, 2005.

What are the top three papers (not yours) you have read recently?
Fleischhacker WW, Keet IPM, Kahn RS (2005). The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial. Schizophrenia Research, 78: 147-156.

Lieberman JA, Stroup ST, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353: 1209-1223.

Fanous AH, van den Oord EJ, Riley BP et al. (2005). Relationship between a high risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry, 162: 1824-1832.

Research Participants
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright